Beam Therapeutics Inc
Beam Therapeutics Inc (BEAM) Covered Calls
Beam Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 6.75%, low versus the past year. BEAM's highest covered call setup is the $30.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 43.54% out of the money with 28 days to expiration, a 43.78% return until expiration, and a 570.70% theoretical annualized return. Across the setups shown, annualized returns run from 92.12% to 570.70% at strikes between $23.00 and $50.00, with 28 to 427 days to expiration, as of Nov 20, 2026.
Read more
Running BEAM covered calls helps you generate income from Beam Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BEAM covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If BEAM stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BEAM covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BEAM covered call is worth writing.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.
| 2026-12-18 | 28 | 30.00 | 43.54 | 0.05 | 1.00 | 915.00 | 43.78 | 570.70 | -0.24 | +0.17 | 39 | 0.95 |
| 2026-12-18 | 28 | 26.00 | 24.40 | 0.20 | 2.80 | 530.00 | 25.36 | 330.57 | -0.96 | +0.35 | 9 | 2.60 |
| 2027-01-15 | 56 | 30.00 | 43.54 | 0.30 | 2.00 | 940.00 | 44.98 | 293.15 | -1.44 | +0.26 | 470 | 1.70 |
| 2026-12-18 | 28 | 23.00 | 10.05 | 0.10 | 1.90 | 220.00 | 10.53 | 137.22 | -0.48 | +0.37 | 37 | 1.80 |
| 2027-01-15 | 56 | 24.00 | 14.83 | 1.00 | 2.00 | 410.00 | 19.62 | 127.86 | -4.78 | +0.39 | 11 | 1.00 |
| 2028-01-21 | 427 | 50.00 | 139.23 | 0.25 | 5.00 | 2935.00 | 140.43 | 120.04 | -1.20 | +0.32 | 1,977 | 4.75 |
| 2027-02-19 | 91 | 26.00 | 24.40 | 0.80 | 4.90 | 590.00 | 28.23 | 113.23 | -3.83 | +0.45 | 4 | 4.10 |
| 2027-02-19 | 91 | 25.00 | 19.62 | 1.15 | 2.65 | 525.00 | 25.12 | 100.75 | -5.50 | +0.40 | 223 | 1.50 |
| 2027-05-21 | 182 | 31.00 | 48.33 | 0.10 | 4.90 | 1020.00 | 48.80 | 97.88 | -0.48 | +0.38 | 17 | 4.80 |
| 2027-02-19 | 91 | 24.00 | 14.83 | 1.70 | 2.55 | 480.00 | 22.97 | 92.12 | -8.13 | +0.44 | 35 | 0.85 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank6.75% Low
- Market cap (M$)2,163
- 52 weeks high-45.37%
- 52 weeks low2.50%
- Analyst recommendationStrong Buy
1.25 - Target price$48.93
134.11% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-03
- P/E—
- Future P/E—
- EPS (ttm)-1.04
- EPS growth next 5 years—
As of Nov 20, 2026